GTX, INC. – Trademark Portfolio
Entity Type: 03
GTX, INC. holds 22 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 18 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include FARESTON. The owner is based in MEMPHIS, TN.
3 NORTH DUNLAP AVENUE
VAN VLEET BUILDING, 3RD FLOOR
MEMPHIS, TN 38163
Showing of trademarks Trademarks
Trademark Classifications
GTX, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does GTX, INC. have?
GTX, INC. has 22 U.S. trademarks filed with the USPTO. Of these, 1 registered, 10 abandoned, 11 cancelled.
What trademark classes does GTX, INC. file in?
GTX, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are GTX, INC.'s most well-known trademarks?
GTX, INC.'s registered trademark portfolio includes well-known marks such as FARESTON. These are among 1 currently registered trademark in the portfolio.
What is GTX, INC.'s trademark registration success rate?
GTX, INC. has a 5% trademark registration rate, with 1 out of 22 resolved applications resulting in successful registration. Currently, 0 applications are pending review.